BTIG Research Boosts Intuitive Surgical (NASDAQ:ISRG) Price Target to $421.00

Intuitive Surgical (NASDAQ:ISRG) had its target price boosted by BTIG Research from $412.00 to $421.00 in a report released on Friday morning, Benzinga reports. BTIG Research currently has a buy rating on the medical equipment provider’s stock.

A number of other research analysts have also recently commented on the company. Stifel Nicolaus raised their price target on Intuitive Surgical from $420.00 to $430.00 and gave the stock a buy rating in a research report on Monday, April 8th. Mizuho raised their price target on Intuitive Surgical from $350.00 to $390.00 and gave the stock a neutral rating in a research report on Thursday, January 25th. Royal Bank of Canada raised their price target on Intuitive Surgical from $400.00 to $432.00 and gave the stock an outperform rating in a research report on Wednesday, January 24th. Wells Fargo & Company raised their price target on Intuitive Surgical from $363.00 to $416.00 and gave the stock an overweight rating in a research report on Friday, January 19th. Finally, Truist Financial raised their price target on Intuitive Surgical from $390.00 to $435.00 and gave the stock a buy rating in a research report on Wednesday, January 24th. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $396.17.

Intuitive Surgical Price Performance

ISRG stock opened at $368.93 on Friday. The stock has a market capitalization of $130.77 billion, a price-to-earnings ratio of 66.59, a PEG ratio of 5.69 and a beta of 1.36. The business’s fifty day moving average price is $386.57 and its two-hundred day moving average price is $344.41. Intuitive Surgical has a fifty-two week low of $254.85 and a fifty-two week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.00 EPS. Research analysts expect that Intuitive Surgical will post 4.93 EPS for the current year.

Insider Activity at Intuitive Surgical

In related news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $370.20, for a total transaction of $740,400.00. Following the sale, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,373,093.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $370.20, for a total transaction of $740,400.00. Following the sale, the director now directly owns 25,319 shares in the company, valued at approximately $9,373,093.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, President David J. Rosa sold 80,710 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the sale, the president now owns 163,399 shares in the company, valued at $63,607,962.72. The disclosure for this sale can be found here. In the last three months, insiders have sold 248,418 shares of company stock valued at $95,927,097. 0.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Intuitive Surgical

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of Intuitive Surgical by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock worth $8,730,184,000 after purchasing an additional 196,316 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Intuitive Surgical by 1.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after purchasing an additional 272,741 shares during the period. Edgewood Management LLC lifted its position in shares of Intuitive Surgical by 7.9% in the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after purchasing an additional 374,667 shares during the period. Jennison Associates LLC lifted its position in shares of Intuitive Surgical by 6.4% in the 3rd quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider’s stock worth $1,340,205,000 after purchasing an additional 274,692 shares during the period. Finally, Fisher Asset Management LLC lifted its position in shares of Intuitive Surgical by 2.0% in the 4th quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock worth $1,516,222,000 after purchasing an additional 88,977 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.